Scott N. Boyle - 13 Feb 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Business Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 13 Feb 2024
Net transactions value: -$11,330
Form type: 4
Filing time: 15 Feb 2024, 17:03:05 UTC
Previous filing: 19 Sep 2023
Next filing: 08 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Tax liability	$11,330	-1,735	-6.5%	$6.53	25,030	13 Feb 2024	Direct	F1
transaction	CCCC	Common Stock	Award	$0	+27,300	+109%	$0.000000	52,330	14 Feb 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+122,800		$0.000000	122,800	14 Feb 2024	Common Stock	122,800	$7.31	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
F2	Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
F3	The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.